Zyban: A Clinically Proven Aid for Smoking Cessation
Zyban
| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.00 | $40.00 (0%) | 🛒 Add to cart |
| 20 | $3.00 | $80.00 $60.00 (25%) | 🛒 Add to cart |
| 30 | $2.33 | $120.00 $70.00 (42%) | 🛒 Add to cart |
| 60 | $1.33 | $240.00 $80.00 (67%) | 🛒 Add to cart |
| 90 | $1.00 | $360.00 $90.00 (75%) | 🛒 Add to cart |
| 120 | $0.83 | $480.00 $100.00 (79%) | 🛒 Add to cart |
| 180 | $0.75 | $720.00 $135.00 (81%) | 🛒 Add to cart |
| 270 | $0.67 | $1080.00 $180.00 (83%) | 🛒 Add to cart |
| 360 | $0.58
Best per pill | $1440.00 $210.00 (85%) | 🛒 Add to cart |
Similar products
Zyban (bupropion hydrochloride) is a prescription medication specifically developed to support adults in their journey to quit smoking. Unlike nicotine replacement therapies, Zyban works by affecting neurotransmitters in the brain associated with nicotine addiction and withdrawal. It is a non-nicotine pharmacotherapy that reduces the urge to smoke and alleviates withdrawal symptoms, thereby increasing the likelihood of long-term abstinence. Clinical trials have demonstrated its efficacy when used as part of a comprehensive smoking cessation program that includes behavioral support.
Features
- Active ingredient: Bupropion hydrochloride
- Available in extended-release (XL) tablets: 150 mg and 300 mg strengths
- Non-nicotine-based mechanism of action
- Prescription-only medication
- Requires gradual dose titration at initiation
Benefits
- Significantly reduces the severity of nicotine cravings and withdrawal symptoms.
- Doubles the chances of long-term smoking cessation compared to placebo when used as directed.
- Does not contain nicotine, eliminating concerns about nicotine replacement.
- Can help manage weight concerns often associated with quitting smoking.
- Provides a structured pharmacological approach to complement behavioral counseling.
- Supported by extensive clinical research and real-world evidence.
Common use
Zyban is indicated as an aid to smoking cessation treatment in adults. It is intended for use in patients who are motivated to quit smoking and should be used as part of a comprehensive cessation program that includes educational and behavioral support. Treatment is typically initiated while the patient is still smoking, with a target quit date set for the end of the first week or beginning of the second week of therapy. The full course of treatment usually lasts 7 to 12 weeks, though duration may be adjusted based on clinical judgment and patient progress.
Dosage and direction
The recommended dosage for Zyban is 150 mg once daily for the first 3 days, followed by an increase to 150 mg twice daily. There should be an interval of at least 8 hours between doses, and the second dose should not be taken too close to bedtime to minimize the risk of insomnia. The maximum recommended dose is 300 mg per day. Tablets should be swallowed whole and not crushed, divided, or chewed, as this may alter the release profile and increase the risk of adverse effects, including seizures. Treatment should be continued for 7 to 12 weeks; if abstinence has not been achieved by week 7, the likelihood of success is low, and discontinuation should be considered.
Precautions
Patients should be monitored for neuropsychiatric symptoms, including changes in behavior, hostility, agitation, depressed mood, and suicidal thoughts or behavior. Zyban should be used with extreme caution in patients with a history of seizure disorder, cranial trauma, or other predisposing conditions, as it lowers the seizure threshold. It is also contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa due to the higher incidence of seizures in such populations. Caution is advised in patients with hepatic or renal impairment, and dose adjustment may be necessary. Zyban may increase blood pressure; regular monitoring is recommended.
Contraindications
Zyban is contraindicated in patients with a seizure disorder or history of seizures. It must not be used in patients with a current or prior diagnosis of bulimia or anorexia nervosa. Concomitant use with monoamine oxidase inhibitors (MAOIs) is contraindicated; at least 14 days should elapse between discontinuation of an MAOI and initiation of Zyban. It is also contraindicated in patients who have shown hypersensitivity to bupropion or any other component of the formulation. Zyban should not be used in patients undergoing abrupt discontinuation of alcohol or sedatives, including benzodiazepines.
Possible side effects
Common adverse reactions include dry mouth, insomnia, nausea, dizziness, and anxiety. Less frequently, patients may experience tremors, rash, sweating, tinnitus, and agitation. There is a dose-dependent risk of seizure (approximately 0.1% at 300 mg/day and 0.4% at 400 mg/day). Other serious side effects may include severe allergic reactions, angioedema, Stevens-Johnson syndrome, and neuropsychiatric events such as suicidal ideation and behavior. Hypertension, including severe elevations, has been reported. Patients should be advised to report any unusual symptoms promptly.
Drug interaction
Zyban is metabolized primarily by CYP2B6 and inhibits CYP2D6. Concomitant use with other drugs that lower the seizure threshold (e.g., antipsychotics, antidepressants, theophylline, systemic corticosteroids) should be avoided. It may increase levels of drugs metabolized by CYP2D6, such as certain antidepressants (e.g., SSRIs, tricyclics), antipsychotics (e.g., haloperidol, risperidone), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., flecainide, propafenone). Caution is advised with levodopa and amantadine due to increased risk of adverse effects. Avoid use with other bupropion-containing products.
Missed dose
If a dose is missed, the patient should skip the missed dose and take the next dose at the regularly scheduled time. Do not double the dose to make up for a missed one, as this may increase the risk of adverse effects, including seizure. Patients should be advised to maintain the prescribed dosing schedule and contact their healthcare provider if they have questions about missed doses.
Overdose
Overdose may lead to seizures, hallucinations, loss of consciousness, sinus tachycardia, and ECG changes such as QRS prolongation. Fatal outcomes have been reported, especially with mixed overdoses involving other drugs. In case of suspected overdose, immediate medical attention is required. Management includes ensuring airway patency, oxygenation, and ventilation. ECG monitoring is recommended. Seizures should be treated with benzodiazepines; additional anticonvulsants may be necessary. There is no specific antidote for bupropion overdose.
Storage
Store at room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F and 86°F). Keep the medication in its original container, tightly closed, and out of reach of children and pets. Protect from light and moisture. Do not store in bathrooms or other areas with high humidity. Dispose of unused or expired medication properly, in accordance with local regulations, to prevent accidental ingestion or misuse.
Disclaimer
This information is intended for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Do not disregard professional medical advice or delay in seeking it because of something you have read here. Individual patient responses to Zyban may vary, and only a healthcare professional can determine if this medication is appropriate for you.
Reviews
Clinical studies and patient reports generally reflect positive outcomes with Zyban when used as part of a structured smoking cessation program. Many users report a significant reduction in cravings and an increased ability to resist smoking. However, experiences with side effects such as insomnia and dry mouth are common. Overall, Zyban is regarded as an effective option for those committed to quitting, particularly when combined with behavioral support. Long-term success rates emphasize the importance of adherence to the prescribed regimen and ongoing motivation.